Treating prostate cancer with immunotherapy remains challenging. However, researchers at City of Hope have developed a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, and the initial results of the first-in-human PhaseRead More…
In recent years, Chimeric Antigen Receptor (CAR) technology has made significant progress in the treatment of hematologic malignancies, particularly in acute lymphoblastic leukemia (ALL), lymphoma, and plasma cell myeloma (PCM). However, theRead More…
Activated T cells with certain surface markers, such as checkpoint inhibitor proteins, are regulated by another type of immune system cell—natural killer (NK) cells. In this way, the body likely suppresses destructiveRead More…
T-cell receptor (TCR) gene therapy is a form of cellular immunotherapy where peripheral blood T cells from cancer patients are genetically engineered ex vivo to express tumor-specific TCRs before being reintroduced intoRead More…
T-cell receptor-engineered T cells (TCR-T) represent a form of cellular immunotherapy and a subtype of adoptive cell transfer (ACT). It involves the identification and selection of TCR sequences capable of specifically bindingRead More…
The use of modified chimeric antigen receptor (CAR) T cells (CAR-T) in immunotherapy has significantly improved the survival rates of pediatric patients with relapsed leukemia. However, these therapies are not as effectiveRead More…
In a recent study conducted by researchers from institutions including the MD Anderson Cancer Center at the University of Texas, USA, it has been discovered that the loss of metabolic capacity inRead More…
Since the world’s first chimeric antigen receptor (CAR)-T cell therapy was approved for marketing in 2017, the Food and Drug Administration (FDA) has approved a total of six CAR-T cell therapies toRead More…
Immune checkpoint inhibitors activate the host immune system to defend against tumors, and although this cancer therapy has shown remarkable success today, the chances of patient response to the therapy are stillRead More…